AMG 208

Drug Profile

AMG 208

Alternative Names: AMG-208

Latest Information Update: 30 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 14 Apr 2015 MD Anderson Cancer Center and Amgen withdraw a phase II trial in castrate-resistant prostate cancer (Metastatic disease) in USA prior to enrolment (NCT02420587)
  • 01 Dec 2014 Amgen completes a phase I trial in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (NCT00813384)
  • 05 Feb 2010 Phase-I development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top